\babel@toc {english}{}
\contentsline {chapter}{\numberline {1}Transcription}{4}{chapter.1}% 
\contentsline {section}{\numberline {1.1}Transcription initiation}{4}{section.1.1}% 
\contentsline {section}{\numberline {1.2}Chromatin remodeling}{6}{section.1.2}% 
\contentsline {subsubsection}{\numberline {1.2.0.1}Techniques to study chromatin remodelling}{6}{subsubsection.1.2.0.1}% 
\contentsline {section}{\numberline {1.3}Nucleosome organization}{7}{section.1.3}% 
\contentsline {subsection}{\numberline {1.3.1}Nucleosome remodelling}{7}{subsection.1.3.1}% 
\contentsline {subsection}{\numberline {1.3.2}Chromatin Immunoprecipitation}{9}{subsection.1.3.2}% 
\contentsline {subsection}{\numberline {1.3.3}Main nucleosome modifications in promoters:}{9}{subsection.1.3.3}% 
\contentsline {subsubsection}{\numberline {1.3.3.1}RT-qPCR based detection of 5' RNA transcripts of inactive genes}{10}{subsubsection.1.3.3.1}% 
\contentsline {subsubsection}{\numberline {1.3.3.2}Global run-on sequencing (GRO-seq)}{11}{subsubsection.1.3.3.2}% 
\contentsline {subsubsection}{\numberline {1.3.3.3}Transcription pausing mechanism}{11}{subsubsection.1.3.3.3}% 
\contentsline {section}{\numberline {1.4}Transcription elongation}{13}{section.1.4}% 
\contentsline {subsection}{\numberline {1.4.1}Structural basis of the nucleosome transition during RNA pol II passage - Kujirai et al 2018}{13}{subsection.1.4.1}% 
\contentsline {subsubsection}{\numberline {1.4.1.1}Nucleosome structure}{13}{subsubsection.1.4.1.1}% 
\contentsline {subsubsection}{\numberline {1.4.1.2}Cryo-EM}{14}{subsubsection.1.4.1.2}% 
\contentsline {subsubsection}{\numberline {1.4.1.3}Summary of the main results}{15}{subsubsection.1.4.1.3}% 
\contentsline {subsubsection}{\numberline {1.4.1.4}Template looping}{15}{subsubsection.1.4.1.4}% 
\contentsline {subsubsection}{\numberline {1.4.1.5}Structural basis of nucleosome disassembly and reassembly by RNA P II elongation complex with FACT - Ehara et al.}{16}{subsubsection.1.4.1.5}% 
\contentsline {section}{\numberline {1.5}Transcription termination}{17}{section.1.5}% 
\contentsline {subsection}{\numberline {1.5.1}Promoter reporter assay}{17}{subsection.1.5.1}% 
\contentsline {subsection}{\numberline {1.5.2}Promoter types}{18}{subsection.1.5.2}% 
\contentsline {subsection}{\numberline {1.5.3}Transcription factor binding}{19}{subsection.1.5.3}% 
\contentsline {chapter}{\numberline {2}Transcription regulation and its deregulation in cancer}{21}{chapter.2}% 
\contentsline {subsubsection}{\numberline {2.0.0.1}Mediator complex}{21}{subsubsection.2.0.0.1}% 
\contentsline {subsection}{\numberline {2.0.1}Wnt signalling pathway}{23}{subsection.2.0.1}% 
\contentsline {subsubsection}{\numberline {2.0.1.1}$\beta $ -catenin structure}{24}{subsubsection.2.0.1.1}% 
\contentsline {subsubsection}{\numberline {2.0.1.2}\textbf {The canonical Wnt/$\beta $ -catenin pathway is crucially involved in colorectal cancer}}{25}{subsubsection.2.0.1.2}% 
\contentsline {section}{\numberline {2.1}6- Transcriptional Control in Cancer}{27}{section.2.1}% 
\contentsline {section}{\numberline {2.2}CREP/p300}{27}{section.2.2}% 
\contentsline {subsubsection}{\numberline {2.2.0.1}CREP/p300 structure}{27}{subsubsection.2.2.0.1}% 
\contentsline {subsection}{\numberline {2.2.1}\textbf {TSSa-RNAs transcription}}{29}{subsection.2.2.1}% 
\contentsline {subsubsection}{\numberline {2.2.1.1}Properties of eRNAs}{30}{subsubsection.2.2.1.1}% 
\contentsline {subsubsection}{\numberline {2.2.1.2}\textbf {Assessing whether the CRC 8q24 risk region acts as an enhancer}}{31}{subsubsection.2.2.1.2}% 
\contentsline {chapter}{\numberline {3}Chromsome domains and oncogene activation}{33}{chapter.3}% 
\contentsline {section}{\numberline {3.1}7- Transcriptional Control in Cancer}{33}{section.3.1}% 
\contentsline {subsubsection}{\numberline {3.1.0.1}Cohesin mediates transcriptional insulation by CCCTC-binding factor}{37}{subsubsection.3.1.0.1}% 
\contentsline {subsubsection}{\numberline {3.1.0.2}Chromosome Conformation Capture (3C)}{40}{subsubsection.3.1.0.2}% 
\contentsline {subsubsection}{\numberline {3.1.0.3}Hi-C approach}{40}{subsubsection.3.1.0.3}% 
\contentsline {subsubsection}{\numberline {3.1.0.4}Optimization of Hi-C approach}{42}{subsubsection.3.1.0.4}% 
\contentsline {subsubsection}{\numberline {3.1.0.5}Promoter-Enhancer Communication Occurs Primarily within Insulated neighbourhoods}{45}{subsubsection.3.1.0.5}% 
\contentsline {subsection}{\numberline {3.1.1}Super-enhancers}{51}{subsection.3.1.1}% 
\contentsline {section}{\numberline {3.2}How is a SE generated during tumorigenesis?}{52}{section.3.2}% 
\contentsline {subsection}{\numberline {3.2.1}How cancer cells take advantage of super-enhancers}{54}{subsection.3.2.1}% 
\contentsline {section}{\numberline {3.3}The role of MYC in cancer cells}{55}{section.3.3}% 
\contentsline {subsection}{\numberline {3.3.1}Key aspect of MYC in tumorigenesis}{56}{subsection.3.3.1}% 
\contentsline {subsubsection}{\numberline {3.3.1.1}MYC transcription factor forms a heterodimer with MAX}{56}{subsubsection.3.3.1.1}% 
\contentsline {subsection}{\numberline {3.3.2}By which major mechanism or pathway MYC proteins promote tumorigenesis?}{57}{subsection.3.3.2}% 
\contentsline {chapter}{\numberline {4}Targeting transcription in cancer}{59}{chapter.4}% 
\contentsline {subsubsection}{\numberline {4.0.0.1}Age-related remodellling of \textbf {oesophageal epithelia by mutated cancer drivers}}{59}{subsubsection.4.0.0.1}% 
\contentsline {subsubsection}{\numberline {4.0.0.2}Key points}{62}{subsubsection.4.0.0.2}% 
\contentsline {subsection}{\numberline {4.0.1}Target transcription in cancer}{63}{subsection.4.0.1}% 
\contentsline {section}{\numberline {4.1}15- Transcriptional Control in Cancer}{65}{section.4.1}% 
\contentsline {section}{\numberline {4.2}BRD4}{65}{section.4.2}% 
\contentsline {subsubsection}{\numberline {4.2.0.1}Selective inhibition of Tumor Oncogenes by Disruption of Super-Enhancers}{65}{subsubsection.4.2.0.1}% 
\contentsline {section}{\numberline {4.3}YAP/TAZ}{66}{section.4.3}% 
\contentsline {section}{\numberline {4.4}TEAD}{68}{section.4.4}% 
\contentsline {subsection}{\numberline {4.4.1}YAP/TAZ/TEAD}{68}{subsection.4.4.1}% 
\contentsline {section}{\numberline {4.5}17- Transcriptional Control in Cancer}{69}{section.4.5}% 
\contentsline {section}{\numberline {4.6}Nuclear receptors}{69}{section.4.6}% 
\contentsline {subsection}{\numberline {4.6.1}Estrogen receptor \(\alpha \)}{70}{subsection.4.6.1}% 
\contentsline {subsection}{\numberline {4.6.2}ER$\alpha $) in breast cancer}{71}{subsection.4.6.2}% 
\contentsline {subsubsection}{\numberline {4.6.2.1}Mechanisms provoking breast cancer drug resistance}{72}{subsubsection.4.6.2.1}% 
\contentsline {subsubsection}{\numberline {4.6.2.2}Summary}{72}{subsubsection.4.6.2.2}% 
\contentsline {subsubsection}{\numberline {4.6.2.3}ER$\alpha $ transcriptional program}{73}{subsubsection.4.6.2.3}% 
\contentsline {chapter}{\numberline {5}Transcription and genome instability}{75}{chapter.5}% 
\contentsline {subsection}{\numberline {5.0.1}R-loops}{75}{subsection.5.0.1}% 
\contentsline {subsubsection}{\numberline {5.0.1.1}R-loop degradation}{76}{subsubsection.5.0.1.1}% 
\contentsline {subsubsection}{\numberline {5.0.1.2}R-loop recognition and distribution}{76}{subsubsection.5.0.1.2}% 
\contentsline {subsubsection}{\numberline {5.0.1.3}VIM-antisense1}{77}{subsubsection.5.0.1.3}% 
\contentsline {subsubsection}{\numberline {5.0.1.4}Main findings}{77}{subsubsection.5.0.1.4}% 
\contentsline {subsection}{\numberline {5.0.2}HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia}{78}{subsection.5.0.2}% 
\contentsline {subsubsection}{\numberline {5.0.2.1}Conclusions}{79}{subsubsection.5.0.2.1}% 
\contentsline {subsection}{\numberline {5.0.3}HOTTIP lncRNA Promotes Hematopoietic Stem Cells Self-Renewal Leading to AML-like Disease in Mice}{80}{subsection.5.0.3}% 
\contentsline {section}{\numberline {5.1}20- Transcriptional Control in Cancer}{80}{section.5.1}% 
\contentsline {section}{\numberline {5.2}Transcription and genome instability II}{80}{section.5.2}% 
\contentsline {subsection}{\numberline {5.2.1}DNA damage}{80}{subsection.5.2.1}% 
\contentsline {subsubsection}{\numberline {5.2.1.1}R loop modified bases}{81}{subsubsection.5.2.1.1}% 
\contentsline {subsection}{\numberline {5.2.2}Apical kinases}{82}{subsection.5.2.2}% 
\contentsline {subsection}{\numberline {5.2.3}Topoisomerases}{84}{subsection.5.2.3}% 
\contentsline {subsubsection}{\numberline {5.2.3.1}A topoisomerase IIb-mediated dsDNA break required for Regulated Transcription}{84}{subsubsection.5.2.3.1}% 
\contentsline {subsubsection}{\numberline {5.2.3.2}BRCA1}{85}{subsubsection.5.2.3.2}% 
\contentsline {subsubsection}{\numberline {5.2.3.3}Stark et al.}{85}{subsubsection.5.2.3.3}% 
\contentsline {chapter}{\numberline {6}Role of transcription in DNA damage response and repair}{87}{chapter.6}% 
\contentsline {subsection}{\numberline {6.0.1}Biogenesis of canonical miRNA}{87}{subsection.6.0.1}% 
\contentsline {subsection}{\numberline {6.0.2}DICER and DROSH regulation of DDR and checkpoint enforcement}{89}{subsection.6.0.2}% 
\contentsline {subsection}{\numberline {6.0.3}DDRNAs}{89}{subsection.6.0.3}% 
\contentsline {subsubsection}{\numberline {6.0.3.1}DDRNAs and dilncRNAs regulate DDR and DNA repair}{91}{subsubsection.6.0.3.1}% 
\contentsline {subsection}{\numberline {6.0.4}RNA Pol II recruitment at DSBs}{92}{subsection.6.0.4}% 
\contentsline {chapter}{\numberline {7}Telomeres and telomere transcription in cancer}{93}{chapter.7}% 
\contentsline {subsection}{\numberline {7.0.1}What are telomeres?}{93}{subsection.7.0.1}% 
\contentsline {subsubsection}{\numberline {7.0.1.1}Telomeres mask chromosome ends from being recognized as double-strand breaks}{93}{subsubsection.7.0.1.1}% 
\contentsline {subsection}{\numberline {7.0.2}Telomere dysfunction in a p53 and Rb mutant setting does not induce cell cycle block}{94}{subsection.7.0.2}% 
\contentsline {subsection}{\numberline {7.0.3}End of replication problem}{95}{subsection.7.0.3}% 
\contentsline {subsubsection}{\numberline {7.0.3.1}Hayflick limit}{97}{subsubsection.7.0.3.1}% 
\contentsline {subsubsection}{\numberline {7.0.3.2}Triggering senescence}{97}{subsubsection.7.0.3.2}% 
\contentsline {subsection}{\numberline {7.0.4}Cell crisis}{98}{subsection.7.0.4}% 
\contentsline {subsection}{\numberline {7.0.5}Telomerase enzyme}{98}{subsection.7.0.5}% 
\contentsline {subsubsection}{\numberline {7.0.5.1}Usage of telomerase}{98}{subsubsection.7.0.5.1}% 
\contentsline {chapter}{\numberline {8}Journal Clubs}{101}{chapter.8}% 
\contentsline {section}{\numberline {8.1}11- JC Transcriptional Control in Cancer}{101}{section.8.1}% 
\contentsline {subsection}{\numberline {8.1.1}MYC Recruits SPT5 to RNA Polymerase II to Promote Processive Transcription Elongation}{101}{subsection.8.1.1}% 
\contentsline {subsubsection}{\numberline {8.1.1.1}Tet-Off/On transgenic system:}{101}{subsubsection.8.1.1.1}% 
\contentsline {subsubsection}{\numberline {8.1.1.2}MYC Controls the Assembly of Transcriptionally Engaged Pol II Complexes}{102}{subsubsection.8.1.1.2}% 
\contentsline {subsubsection}{\numberline {8.1.1.3}CDK7 Activity is Required for Transfer of SPT5 from MYC to Pol II}{102}{subsubsection.8.1.1.3}% 
\contentsline {subsubsection}{\numberline {8.1.1.4}MYC Influences Processivity and Directionality of Pol II after pause release}{102}{subsubsection.8.1.1.4}% 
\contentsline {subsection}{\numberline {8.1.2}BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer}{103}{subsection.8.1.2}% 
\contentsline {subsubsection}{\numberline {8.1.2.1}BRD4 is physically associated with LSD1/NuRD complex}{103}{subsubsection.8.1.2.1}% 
\contentsline {subsubsection}{\numberline {8.1.2.2}BRD4 and the LSD1/NuRD complex occupy SE}{103}{subsubsection.8.1.2.2}% 
\contentsline {subsubsection}{\numberline {8.1.2.3}Decommissioning the BRD4/LSD1/NuRD Complex Leads to JQ1 Resistance}{103}{subsubsection.8.1.2.3}% 
\contentsline {subsubsection}{\numberline {8.1.2.4}Elimination of PELI1 Improves the Therapeutic Efficacy of JQ1 in Breast Cancer Cells}{104}{subsubsection.8.1.2.4}% 
\contentsline {subsubsection}{\numberline {8.1.2.5}The Clinicopathological Significance of the PELI1-LSD1-BRD4/LSD1/ NuRD Axis in Breast Cancer}{104}{subsubsection.8.1.2.5}% 
